Off-the-shelf vaccine shows success against deadly cancers
Why it matters: If shown effective in further trials, the vaccine could become a particularly important tool in staving off the return of pancreatic cancer, which sees roughly 80% of surgically removed tumors recur within five years.
What they're saying:"This was a trial all of us in the medical oncology world have been waiting for," said Tracy Proverbs-Singh, an oncologist at Hackensack Meridian's John Theurer Cancer Center.
"We see these patients for five years, we see the recurrences, we have to re-treat them, and it's devastating. And after we finish chemo, there's not a lot we can do."
Go deeper: The peptide vaccine targets the KRAS mutation that occurs in roughly 90% of pancreatic cancers and half of colorectal cancers.
Researchers administered the shot, called ELI-002 2P, to 25 patients who'd received conventional treatments but still had small amounts of cancer left in their bodies and were at high risk of relapse.
Half of patients had no relapse by 16.3 months, and median overall survival was 28.9 months — both exceeding historical norms, per the study in Nature Medicine. The greatest benefit was seen in patients who had strong T cell responses.
At the 20-month mark, 17 of the 25 patients had strong immune responses with 11 of those patients having no recurrence and six having delayed recurrence. The latter successfully underwent further treatment.
"All the 17 were still alive which is why we think there's optimistically, something real going on here, because that's much better than what we might have expected historically," said Zev Wainberg, co-director of the UCLA GI Oncology Program and one of the lead authors.
Yes, but: Researchers do not yet understand why eight of the 23 patients did not develop a strong immune response as a result of the vaccine.
Between the lines: Much of the enthusiasm around therapeutic cancer vaccines has centered on personalized mRNA technology.
It is notable that researchers were able to use a non-personalized vaccine because it can be more easily developed at scale.
"It's a big shot in the arm for the pancreatic cancer vaccine, which has been elusive in the context of us being able to get something that's effective in the early stages," said Madappa Kundranda, division chief for cancer medicine at Banner MD Anderson Cancer Center.
Reality check: This is still a small Phase 1 trial and will require a more robust randomized controlled trial.
Wainberg said the team has already completed such a trial and should have results back in 2026.
What to watch: Pancreatic cancer, which has a five-year survival rate of around 13% in the U.S., could be treated very differently within the next two years as multiple new drugs targeting the same mutations are also developed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Doctors Think We Need To Cool It With Our Obsession With This 1 Nutrient
Even a quick walk through the aisles of your local market will confirm what you've probably already suspected — just about everyone wants more protein in their diet. While keto and paleo dieters are centered around it, others are seeking ways to get enough of it through powders, beverages, bars, pasta and snacks. While many consumers are loading up on as much protein as they can get, experts say, we can jump off the 'all protein, all the time' bandwagon and start looking for a more generally balanced diet. Protein Does Lots Of Great Things Dr. Zhaoping Li, chief of the division of clinical nutrition at the David Geffen School of Medicine at UCLA, said protein provides the building blocks of our organs and body, and that it's essential to improve the immune system. 'It's also used to make neurotransmitters, can function as hormones or can provide fuel through glucogenic or ketogenic pathways.' Related: 'Protein is essential for health because it's a central component of all our tissues and bodily functions, such as enzyme secretion and immune function,' said Jorn Trommelen, an expert on nutrition and an assistant professor in the department of human biology at Maastricht University in the Netherlands. 'Bodily proteins are continuously broken down to amino acids, which are recycled in new proteins. But there is a net loss of bodily protein in the absence of protein ingestion, so dietary protein is essential to maintain our tissue mass and function.' Most People In The Developed World Are Getting More Than Enough When you read that list of important jobs protein does, it makes sense that you'd want to get lots of it in your diet. But experts are saying that, as so often happens, we've gone overboard with our latest 'superfood' ingredient. 'The vast majority of Americans already consume enough protein, and we don't need more,' said Dr. Dariush Mozaffarian, director at the Tufts Food is Medicine Institute, and a cardiologist, public health scientist and professor at the Friedman School of Nutrition Science and Policy. 'The nation's growing obsession with protein arises more from misconceptions than value for health.' 'We've been sold the idea that protein is the golden ticket to health, but this has far more to do with marketing than with science,' said Dr. Luke Wilson, a general practitioner, lifestyle medicine practitioner and board director at Doctors for Nutrition, which champions plant-based nutrition for disease prevention and care. 'In reality, our bodies are incredibly efficient at getting what they need from regular, plant-based whole foods. If you're eating enough calories from a variety of plant foods, you're getting enough protein.' Just In Case, Here Are Protein-Deficiency Symptoms The list of protein-deficiency symptoms is somewhat vague and equally rare. Mozaffarian said, 'Unless protein intake is very low for a long time, there are few symptoms. If it's very low and prolonged, then people can experience fatigue, hair loss, muscle loss, skin and nail changes, ankle swelling and brain fog.' Trommelen noted a syndrome known as kwashiorkor, a severe form of malnutrition caused by protein deficiency that can stunt growth, is unlikely to occur in the Western world. Of course, if you're experiencing any of these symptoms or are concerned about your protein intake, it's a good idea to consult with your health care provider, especially if you're undereating or taking weight-loss medication. One Chicken Breast Could Be Enough Protein should account for 10% to 35% of your calories, according to the American Heart Association. On a 2,000-calorie-a-day diet, that's 200 to 700 calories from protein, or 50 to 175 grams. The Department of Agriculture has a calculator of dietary reference intakes to help you determine how much protein you need. The recommended dietary allowance is 0.8 grams of protein per kilogram of body weight, or 0.36 grams per pound. That means a 50-year-old woman who weighs 140 pounds and who doesn't exercise would need 53 grams of protein a day. As examples, 7 ounces of cooked chicken breast contains roughly 50 grams of protein, and so does 5.5 ounces of Greek yogurt eaten with 3 ounces of chicken breast. The American Heart Association says that most people, even athletes, can get enough protein by eating a serving of dairy for each of three meals in a day, plus a piece of meat the size of a deck of cards at lunch and supper. Related: As you get older, protein needs may increase, experts said. 'Older adults slowly lose muscle mass, and there's data suggesting it's perhaps partially because they are less efficient at using dietary protein,' Trommelen noted. 'It's been suggested that older adults should consume up to 1.2 grams per kilogram of weight per day, up from the general recommendation of 0.36 grams, although this is still a topic of debate.' Have You Considered The Rest Of Your Diet? You may also want to consider what other nutrients might help your body do its best. Fewer than 10% of U.S. adultsmeet the daily recommended intake for vegetables (2 to 3 cups a day), and only 20% eat enough fruit (1 1/2 to 2 cups daily). That lack of produce consumption has left us with many nutrient shortfalls, including vitamins A, D, E and C, folate, calcium, magnesium, fiber and potassium. For adolescent and premenopausal females, iron is also a shortfall nutrient. Nutritionists are especially concerned about four nutrients — fiber, calcium, vitamin D and potassium. To Avoid Protein-Related Visceral Fat, Try Strength Training Many of us aren't engaging in lifestyles that will help us absorb protein in the most efficient way possible. If you want more muscle growth, you'll need extra strength training, not extra protein. Mozaffarian said that you've got to be working out on the regular for protein to be able to make a difference. 'Eating more protein is valuable when people are engaged in a regular program of strength training and when they're working out several times per week, where it helps build muscle mass and strength.' Trommelen agreed, saying: 'Physical activity, especially resistance exercise, greatly enhances the body's use of dietary protein.' It's also true that since the body can't store protein, amounts that are more than your body needs end up being used for energy or stored as fat. 'Without a regular program of strength training, eating more protein has little health value,' Mozaffarian said. 'Just eating more protein alone won't build muscle. In fact, excess dietary protein is converted to visceral fat, increasing the risk of insulin resistance and diabetes. That's because when protein intake is high, insulin rises, just like it does with starch or sugar intakes. In studies across the world, people who have the highest levels of protein actually have higher risk of diabetes.' Recommended Sources Of Protein 'If you want to build muscle mass, engage in a regular program of strength training or resistance exercise, and focus on healthy food sources of protein,' Mozaffarian said. 'Otherwise, emphasize a generally healthy diet, and rather than being obsessed with protein, seek out minimally processed fruits, vegetables, nuts, seeds, legumes, whole grains, plant oils, fish and yogurt. Avoid soda, candy, processed meat and ultraprocessed foods high in starch, sugar or salt. 'Focus on the food source and its overall impact on your health, rather than the grams of protein,' Mozaffarian said. 'Avoid processed meats, ultraprocessed foods like protein bars and protein powders. Protein-rich foods with evidence for general health benefits include fish, shellfish, yogurt, cheese and milk. Legumes, grains and nuts also provide protein and substantial health benefits. Unprocessed red meats are OK in moderation, up to two servings per week.' Related: Head For The Produce Aisle Wilson wrapped it up this way: 'If you're living in a high-income country and you're eating enough calories, you're not protein deficient. We need to stop pathologizing normal fatigue or poor diet quality as being caused by not enough protein.' 'The real health benefits come from eating fewer ultra-processed foods, reducing consumption of animal products and building meals around beans, whole grains, vegetables and fruits. That's a way of eating that lowers your risk of heart disease, type 2 diabetes and cancer — and it gives you all the protein you need, without even trying.' Related... Protein Isn't Just For Weightlifters. Here's How Much Everyone Should Eat. The Best Proteins To Eat If You Want The Most Bang For Your Buck Feeding Your Kid Protein Powder? These Pediatricians Want You To Reconsider.
Time Business News
3 hours ago
- Time Business News
D-Dimer Test Flags Clot Risk, Aids Broader Diagnosis
D Dimer Test is a kind of blood test detecting the presence of D-dimer in the blood. D-dimer is a protein fragment of fibrin formed after Fibrinolysis degradation of blood clot. It is helpful to diagnose the conditions with abnormal blood clots formation and breakdown, intravascular fibrinolysis, and coagulation. High D-dimer levels indicate clinical suspicion of a blood clot and needs ultrasound, CT angiography, scans could be performed to confirm the presence of clot and location of clot. D-Dimer test is not specific to any disease. D-Dimer test is not specific to any disease and thus is performed in conjunction with other evaluations and diagnostic tests. 0.5 is measured as normal range for D-dimer and greater than 0.5 is measured to be positive. D-dimer decreases under abnormal medical case which is measured by specific antibodies. Key Growth Drivers and Opportunities Demand for D-Dimer Testing: Traditional testing is replaced by D-dimer testing, allowing for faster test results, quicker diagnosis, shorter patient wait times, and better patient outcomes overall. D-Dimer testing to be more widely used by customers offering compelling advantages. Moreover, the growing prevalence of lung and cardiovascular illnesses might, in extreme circumstances, lead to potentially fatal blood clot problems, which propels D-Dimer Test. Rising Genetic Disorders: Increasing cases of Thrombus embolism along with various cardiovascular and pulmonary diseases that could be life threating due to clot formation increases the demand for D-Dimer Test globally. D-dimer functions as valuable marker in various clinical conditions such as HIV, atrial fibrillation, coronary artery disease. New technological advancement such as development of aptamers, reducing use of antibodies for D-dimer testing being cost-effective, long-lasting boosts D-Dimer Test widening scope for these tests. Challenges The major challenge consists of inadequate skilled professionals and trained professionals unable to perform the test properly and lack of knowledge leads to false results and restrains the D-Dimer test Market. High cost and poor reimbursement policies restrains people to take such tests for proper diagnosis increasing the prevalence of disease and deaths. Innovation and Expansion Study Links Long COVID Brain Fog to Blood Microclots In September 2023, Finding was published in Nature Medicine, suggesting links between brain fog in long COVID and 'micro clots' in the blood. These clots often contain misfolded fibrinogen proteins that prevent the clots from breaking down, and this effect can clog blood vessels and block oxygen flow to the brain and other organs. Blood tests for both D-dimer and fibrinogen are already standard around the world, so researchers had plenty of available data to check whether the same phenomenon occurred in other groups of patients. LumiraDx Expands Rapid Testing for VTE and Heart Failure In June 2022, LumiraDx Limited, a next-generation point of care Diagnostics Company, announced its cardiovascular offering with a CE Mark for its new NT-proBNP test to aid in the diagnosis of CHF and an updated CE Mark for its D-Dimer test to now rule out venous thromboembolism (VTE) in symptomatic patients. With these two additions, the LumiraDx Platform can further support clinicians in quickly and accurately assessing patient symptoms for both VTE and heart failure at the point of care. The LumiraDx NT-proBNP test is a rapid microfluidic immunofluorescence assay for the quantitative measurement of NT-proBNP in human capillary, venous whole blood and plasma specimens. Inventive Sparks, Expanding Markets The major companies present in the D-dimer test market are Bio/Data Corporation, Becton Dickinson BV, Sysmex Corporation, Abbott Laboratories, Inc., Dickinson and Company, Hoffman-La Roche Ltd., among others. Global companies work to foster lasting innovation, grow their markets, and provide quality goods and services. They concentrate on improving customer experience, applying tech, and creating strong operations. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
Axios
17 hours ago
- Axios
Off-the-shelf vaccine shows success against deadly cancers
An experimental vaccine targeting one of the most common genetic drivers of hard-to-treat pancreatic and colorectal cancers prevented their recurrence, raising hopes for an "off the shelf" treatment that can train the immune system to attack malignancies. Why it matters: If shown effective in further trials, the vaccine could become a particularly important tool in staving off the return of pancreatic cancer, which sees roughly 80% of surgically removed tumors recur within five years. What they're saying:"This was a trial all of us in the medical oncology world have been waiting for," said Tracy Proverbs-Singh, an oncologist at Hackensack Meridian's John Theurer Cancer Center. "We see these patients for five years, we see the recurrences, we have to re-treat them, and it's devastating. And after we finish chemo, there's not a lot we can do." Go deeper: The peptide vaccine targets the KRAS mutation that occurs in roughly 90% of pancreatic cancers and half of colorectal cancers. Researchers administered the shot, called ELI-002 2P, to 25 patients who'd received conventional treatments but still had small amounts of cancer left in their bodies and were at high risk of relapse. Half of patients had no relapse by 16.3 months, and median overall survival was 28.9 months — both exceeding historical norms, per the study in Nature Medicine. The greatest benefit was seen in patients who had strong T cell responses. At the 20-month mark, 17 of the 25 patients had strong immune responses with 11 of those patients having no recurrence and six having delayed recurrence. The latter successfully underwent further treatment. "All the 17 were still alive which is why we think there's optimistically, something real going on here, because that's much better than what we might have expected historically," said Zev Wainberg, co-director of the UCLA GI Oncology Program and one of the lead authors. Yes, but: Researchers do not yet understand why eight of the 23 patients did not develop a strong immune response as a result of the vaccine. Between the lines: Much of the enthusiasm around therapeutic cancer vaccines has centered on personalized mRNA technology. It is notable that researchers were able to use a non-personalized vaccine because it can be more easily developed at scale. "It's a big shot in the arm for the pancreatic cancer vaccine, which has been elusive in the context of us being able to get something that's effective in the early stages," said Madappa Kundranda, division chief for cancer medicine at Banner MD Anderson Cancer Center. Reality check: This is still a small Phase 1 trial and will require a more robust randomized controlled trial. Wainberg said the team has already completed such a trial and should have results back in 2026. What to watch: Pancreatic cancer, which has a five-year survival rate of around 13% in the U.S., could be treated very differently within the next two years as multiple new drugs targeting the same mutations are also developed.
